CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

MLA

Appay, Romain, et al. “CDKN2A Homozygous Deletion Is a Strong Adverse Prognosis Factor in Diffuse Malignant IDH-Mutant Gliomas.” Neuro-Oncology, vol. 21, no. 12, Dec. 2019, pp. 1519–28. EBSCOhost, https://doi.org/10.1093/neuonc/noz124.

APA

Appay, R., Dehais, C., Maurage, C.-A., Alentorn, A., Carpentier, C., Colin, C., Ducray, F., Escande, F., Idbaih, A., Kamoun, A., Marie, Y., Mokhtari, K., Tabouret, E., Trabelsi, N., Uro-Coste, E., Delattre, J.-Y., & Figarella-Branger, D. (2019). CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology, 21(12), 1519–1528. https://doi.org/10.1093/neuonc/noz124

Chicago

Appay, Romain, Caroline Dehais, Claude-Alain Maurage, Agusti Alentorn, Catherine Carpentier, Carole Colin, François Ducray, et al. 2019. “CDKN2A Homozygous Deletion Is a Strong Adverse Prognosis Factor in Diffuse Malignant IDH-Mutant Gliomas.” Neuro-Oncology 21 (12): 1519–28. doi:10.1093/neuonc/noz124.